Viracta Therapeutics Stock (NASDAQ:VIRX)
Previous Close
$0.15
52W Range
$0.13 - $1.31
50D Avg
$0.21
200D Avg
$0.55
Market Cap
$6.39M
Avg Vol (3M)
$1.06M
Beta
0.30
Div Yield
-
VIRX Company Profile
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
VIRX Performance
Peer Comparison
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
MREO | Mereo BioPharma Group plc |
EYPT | EyePoint Pharmaceuticals, Inc. |
BMEA | Biomea Fusion, Inc. |
TNYA | Tenaya Therapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
ALXO | ALX Oncology Holdings Inc. |
SQZ | SQZ Biotechnologies Company |
IGMS | IGM Biosciences, Inc. |
RLYB | Rallybio Corporation |
TERN | Terns Pharmaceuticals, Inc. |
CABA | Cabaletta Bio, Inc. |
INZY | Inozyme Pharma, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
VINC | Vincerx Pharma, Inc. |
TRVI | Trevi Therapeutics, Inc. |
TARA | Protara Therapeutics, Inc. |
LPTX | Leap Therapeutics, Inc. |
LYRA | Lyra Therapeutics, Inc. |
BCYC | Bicycle Therapeutics plc |